Yashoda Hospitals, Hyderabad, India Successfully performs the Latest JARVIK Implant Postauricular On a 31 Year Old Uganda Patient

Yashoda Hospitals, Hyderabad, India Department of Cardiology, Cardiothoracic and Heart-Lung mechanical assist devices team has successfully performed the latest JARVIK implant postauricular (behind the ear) driveline on a 31-year-old young patient from Uganda.

Mr. Okwara Joseph is a Footballer by profession. He had developed chest pain while playing football in April ’21 at Uganda.

After he was diagnosed with coronary artery disease along with severe Left Ventricular dysfunction, he has been through repeated hospital admissions in Uganda with complaints of breathlessness, swelling of bilateral lower limbs, and abdominal distension. He was eventually diagnosed with ischemic cardiomyopathy and decided to travel to India for further treatment in November and was admitted at Yashoda Hospitals on December 13th for worsening heart failure symptoms.

A multidisciplinary Team of doctors from Departments of Cardiology, Cardiothoracic, Heart, and Lung mechanical assist device, evaluated the patient thoroughly and was planned for a left ventricular assist device as destination therapy. The latest and most advanced modality of treatment (JARVIK 2000 SERIES) was offered at Yashoda Hospitals with state-of-the-art facilities, the latest and most advanced equipment. Mr. Okwara Joseph was successfully operated on 24th December 2021, got a new lease of life, and was discharged on 28th January 2022 from Yashoda Hospitals, Hyderabad, India.

JARVIK 2000 series is an advanced and latest LVAD device that serves as a destination therapy in Advance Heart failure patients giving a new lease of life to the patients with advanced-stage heart failure. Yashoda Hospitals Director – Dr. Pavan Gorukanti added, “Yashoda Hospitals, Hyderabad has one of the best cardiac, heart and lung transplantation teams in the world with matching infrastructure providing the best-in-class services, latest and best technologies and pioneers in performing the complex procedures.”

Yashoda Hospitals has emerged as a preferred destination for medical value travel for patients across the globe, treating 1000s of patients from over 40 countries. The Group has been providing quality healthcare for 3 decades in virtually every specialty and subspecialty of medicine and surgery. Currently operating with 3 independent hospitals with 2400 beds and an upcoming hospital which is expected to be one of the largest medical facilities in India; with a capacity of 2000 beds.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version